KSKonstantin Svechnikov

Konstantin Svechnikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Konstantin Svechnikov has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Olle Söder

    Department of Women's and Children's Health, Pediatric Endocrinology Unit, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden

    8 shared publications
  • I. Savchuk

    Department of Women's and Children's Health, Pediatric Endocrinology Unit, Karolinska Institute & University Hospital, Stockholm, Sweden

    4 shared publications
  • O. Söder

    Department of Women's and Children's Health, Pediatric Endocrinology Unit, Karolinska Institute & University Hospital, Stockholm, Sweden

    4 shared publications
  • Olle Söder

    Department of Women's and Children's Health, Paediatric Endocrinology Unit, Karolinska Institutet and University Hospital, Stockholm, Sweden

    4 shared publications
  • Irina Svechnikova

    Department of Woman and Child Health, Pediatric Endocrinology Unit, Karolinska Institute and University Hospital Stockholm, Sweden

    3 shared publications
  • Iuliia Savchuk

    Department of Women's and Children's Health, Pediatric Endocrinology Unit, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden

    3 shared publications

Latest Publications

  • Cell Models for Leydig Cell Function and Regulation

    by Konstantin Svechnikov, Jan-Bernd Stukenborg


  • Steroidogenic potential of human fetal kidney at early gestational age

    by I. Savchuk, M.L. Morvan, J.P. Antignac, M. Kurek, B. Le Bizec, O. Söder, K. Svechnikov


  • Ontogenesis of human fetal testicular steroidogenesis at early gestational age

    by I. Savchuk, M.L. Morvan, J.P. Antignac, M. Kurek, B. Le Bizec, O. Söder, K. Svechnikov


  • The human genital tubercle is steroidogenic organ at early pregnancy

    by I. Savchuk, M.L. Morvan, J.P. Antignac, K. Gemzell-Danielsson, B. Le Bizec, O. Söder, K. Svechnikov


  • Open Access

    Androgenic potential of human fetal adrenals at the end of the first trimester

    by I Savchuk, M L Morvan, J P Antignac, K Gemzell-Danielsson, B Le Bizec, O Söder, K Svechnikov

    The onset of steroidogenesis in human fetal adrenal glands (HFA) during the first trimester is poorly investigated. An unresolved question is the capacity of the HFA to produce potent androgen DHT via conventional and/or the backdoor pathway(s) at the end of first trimester, when androgen-responsive organs are developed. Our aim was to explore steroidogenesis and the expression of steroidogenic enzymes and transcription factors in HFA at gestational weeks (GW) 9–12 with focus on their androgenic potential. Steroids in the HFA were analyzed by gas chromatography/mass spectrometry. The expression of steroidogenic enzymes and transcription factors in the HFA at GW9–12 was investigated by qPCR, automated Western blotting and immunohistochemistry. We demonstrated that during GW9–12 HFA produced steroids of the ∆5, ∆4 and the backdoor pathways of the biosynthesis of DHT, though the latter was limited to production of 17α-OH-dihydroprogesterone, androsterone and androstanedione without further conversion to DHT. The only androgens identified in the HFA were testosterone and androsterone, a precursor in the biosynthesis of DHT. We also observed higher levels of CYP17A1 but low expression of 3βHSD2 at GW11–12 in the HFA. Elevated levels of CYP17A1 were associated with an increased expression of SF-1 and GATA-6. Altogether, our data demonstrate that of those steroids analyzed, the only potent androgen directly produced by the HFA at GW9–12 was testosterone. The onset of steroidogenesis in the HFA is a complex process that is regulated by the coordinated action of related transcription factors.


  • Prepubertal onset of obesity negatively impacts on testicular steroidogenesis in rats

    by I.V. Wagner, N. Klöting, N. Atanassova, I. Savchuk, C. Spröte, W. Kiess, O. Söder, K. Svechnikov


  • Resveratrol inhibits steroidogenesis in human fetal adrenocortical cells at the end of first trimester

    by Iuliia Savchuk, Marie‐Line Morvan, Tue Søeborg, Jean‐Philippe Antignac, Kristina Gemzell‐Danielsson, Bruno Le Bizec, Olle Söder, Konstantin Svechnikov

    Scope: Resveratrol has a diverse array of healthful effects on metabolic parameters in different experimental paradigms but has also potential to inhibit steroidogenesis in rodent adrenals. The aim of the present study was to characterize the effects of resveratrol on human fetal adrenal steroidogenesis at gestational weeks (GW) 9–12.Methods and results: Adrenals from aborted fetuses (GW10‐12) were used to prepare primary cultures of human fetal adrenocortical cells (HFAC). HFAC were treated in the presence or absence of ACTH (10 ng/mL) with or without resveratrol (10 μM) for 24 h. The production of steroids by HFAC was analyzed by gas and liquid chromatography coupled to tandem/mass spectrometry. The expression of steroidogenic enzymes at GW 9–12 was quantified by automated Western blotting. We observed that resveratrol significantly suppressed synthesis of dehydroepiandrosterone (DHEA), androstenedione and 11‐deoxicortisol by ACTH‐activated and unstimulated HFAC, which was associated with inhibition of the activities and expression of cytochromes 17α‐hydroxylase/17,20 lyase (CYP17) and 21‐hydroxylase (CYP21) in these fetal adrenocortical cells.Conclusion: Our in vitro findings on the sensitivity of human fetal adrenal steroidogenesis to resveratrol at GW9‐12 suggest that intake of this polyphenol at high doses by women who are at early stages of pregnancy is undesirable.


  • Insulin-Like Peptide 5 Interacts with Sex Hormones and Metabolic Parameters in a Gender and Adiposity Dependent Manner in Humans

    by I. V. Wagner, G. Flehmig, K. Scheuermann, D. Löffler, A. Körner, W. Kiess, M. Stumvoll, A. Dietrich, M. Blüher, N. Klöting, et al.

    Insulin-like peptide 5 (INSL5) is a gut hormone produced by L-cells in the colorectal epithelium and may play a role in the regulation of metabolic processes. The biological role of INSL5 is poorly investigated and nothing is known about the role of this hormone in obese and lean humans. Two cohorts were analyzed in the study. In the first cohort (n=76) the relationship between serum levels of INSL5 and different metabolic and hormonal parameters in obese and lean men and women were investigated. In the second cohort 14 male subjects underwent bariatric surgery. Circulating levels of INSL5 were then measured before and after interventions. We report for the first time that circulating INSL5 interacts with multiple metabolic and hormonal variables in lean and obese men and women and is affected by bariatric surgery. Serum levels of INSL5 negatively correlated with testosterone and blood lipids but positively with cortisol in obese men. In contrast to males, obese women had a strong negative correlation of plasma levels of INSL5 with C-reactive protein (CRP). We observed that adipose tissue loss after bariatric surgery significantly reduced serum levels of INSL5 in obese men with and without Type 2 Diabetes Mellitus (T2DM) that was associated with the restoration of circulating levels of testosterone. All together, our data demonstrated that INSL5 may interact with some metabolic parameters in obese humans and this process is dependent of gender and obesity state.


  • Mono-2-Ethylhexyl Phthalate Stimulates Androgen Production but Suppresses Mitochondrial Function in Mouse Leydig Cells With Different Steroidogenic Potential

    by Iuliia Savchuk, Olle Söder, Konstantin Svechnikov

    Numerous studies have reported on testicular toxicity of phthalates in different experimental paradigms and showed that Leydig cells (LCs) were one of the main targets of phthalate actions. Adverse effects of phthalates on LCs steroidogenesis have been attributed to their metabolites, monophthalates. This study focuses on investigation whether LCs responsiveness to monophthalates action is associated with their potential to produce androgens. We found that of 3 monophthalates investigated [ie, mono-2-ethylhexyl phthalate (MEHP), mono-n-butyl phthalate, and mono-n-benzyl phthalate] only MEHP caused biological effects on the mouse LCs function. This monophthalate stimulated basal steroidogenesis associated with upregulation of StAR protein expression with no effect on hCG-stimulated androgen production by LCs from CBA/Lac and C57BL/6j mouse genotypes were observed. Further, MEHP attenuated ATP production and increased superoxide generation by both phenotypes of mouse LCs that indicated on mitochondrial dysfunction induced by the monophthalate. All together, our data indicate that MEHP-mediated stimulation of steroidogenesis and perturbation in mitochondrial function are not associated with the capacity of the LCs to synthesize androgens. We suggest that this effect of MEHP observed in LCs of rodent origin needs to be taken into consideration in analysis of earlier start of puberty in boys and may highlight a possible influence of phthalates on reproductive health in males.


  • Open Access

    Bortezomib treatment causes long-term testicular dysfunction in young male mice

    by Mi Hou, Emma Eriksson, Konstantin Svechnikov, Kirsi Jahnukainen, Olle Söder, Andreas Meinhardt, Lars Sävendahl

    With increased long-term survivors of childhood cancer patients, therapy-associated infertility has become one of the most common late side-effects and significantly affects their life-quality. Therefore, evaluation of anti-cancer agents on male reproduction and infertility prevention are urgently demanding. The proteasome inhibitor bortezomib has been launched in clinical trials for childhood cancers, however, its potential side effects on reproduction have so far been neither investigated experimentally nor reported in treated children. Thus the present study is designed to explore the impact of bortezomib on male reproductive function and to gain insights into how bortezomib exerts its adverse effects on man gonad, thereby providing pediatric oncologists relevant information.